Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450404 | 0.93 | BCHE (0.55) | BCHELTB4RLTB4R2ALOX5LTA4H | |
| SCHEMBL4453600 | 0.90 | LTB4R (0.55) | BCHELTB4RLTB4R2ALOX5LTA4H | |
| SCHEMBL25047708 | 0.89 | HDAC3 (0.48) | LTB4R2ALOX5L3MBTL1HDAC3HDAC1 | |
| SCHEMBL4449671 | 0.87 | LTB4R (0.55) | BCHELTB4RLTB4R2ALOX5LTA4H | |
| SCHEMBL19352856 | 0.85 | EGFR (0.52) | LTB4RLTB4R2ALOX5L3MBTL1HDAC3 | |
| SCHEMBL7835952 | 0.84 | LTB4R (0.52) | BCHELTB4RLTB4R2ALOX5LTA4H | |
| SCHEMBL7825818 | 0.83 | LTB4R (0.51) | BCHELTB4RLTB4R2ALOX5LTA4H | |
| SCHEMBL19352857 | 0.83 | BACE1 (0.45) | ALOX5 | |
| SCHEMBL3014165 | 0.82 | LTB4R (0.67) | LTB4RLTB4R2ALOX5FFAR1FFAR4 | |
| SCHEMBL18845331 | 0.82 | HDAC3 (0.50) | ALOX5L3MBTL1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7339079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-04 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-16 | — | — | US | disclosed |
| US-6979750-B1 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050267207-A1 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | TPO, TSHR, THRB | BCHE 332/4885LTB4R 496/4885LTB4R2 450/4885 |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | BCHE 337/4885LTB4R 552/4885LTB4R2 503/4885 |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | BCHE 332/4885LTB4R 496/4885LTB4R2 450/4885 |
| US-20050267207-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | BCHE 337/4885LTB4R 552/4885LTB4R2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.